Last week saw a large number of broker notes hitting the wires once again. Three buy ratings that caught my eye are summarised below.
Here's why brokers think investors ought to buy them next week:
CSL Limited (ASX: CSL)
A note out of the Macquarie equities desk reveals that its analysts have retained their outperform rating and lifted the price target on this biotherapeutics company's shares to $300. Macquarie believes CSL is well-positioned for growth thanks to its Idelvion product and its plasma collection network. I agree with Macquarie and would buy CSL shares with a long term view.
Nufarm Limited (ASX: NUF)
Analysts at Morgan Stanley have retained their overweight rating and $7.20 price target on this agricultural chemicals company's shares. According to the note, the broker remains positive on Nufarm despite its disappointing first quarter update. It believes its issues are temporary and investors should take advantage of its share price weakness. Especially given its massive Omega-3 opportunity. I think Morgan Stanley makes some very good points and it could be worth considering a patient investment.
Telstra Corporation Ltd (ASX: TLS)
According to a note out of Morgans, its analysts have retained their add rating and $4.46 price target on this telco giant's shares. The broker appears confident that FY 2020 is the bottom of the cycle for Telstra and it's onwards and upwards from here. In addition to this, Morgans believes Telstra is best positioned to benefit from improving industry conditions. I think Morgans is spot on and feel Telstra is in the buy zone right now.
